on New Drugs (and New Concepts)
5 International Meeting th
in Breast Cancer
ROME, NOVEMBER 9-10, 2017
Regina Elena National Cancer Institute Bastianelli Congress Centre
PRESIDENT: Francesco Cognetti
WELCOME LETTER
D
ear Friends and Colleagues,it is with pleasure that I welcome you to Rome for the 5th International Meeting on New Drugs (and New Concepts) in Breast Cancer, bringing together clinicians, mainly medical oncologists, and researchers including this year a substantial translational research component. The issues enlisted in this preliminary program, in particular including data from clinical trials stemming from that original basic research, demonstrate how the translation of basic research into practical clinical tools is particularly active in this disease.
The program has been designed in the pursuit of excellence and, as usually, all lectures will be presented by an international distinguished outstanding faculty who will report all their experiences and developments.
I look forward to joining you and I also hope you can enjoy a unique and pleasant stay in our wonderful City.
Francesco Cognetti
CONGRESS VENUE AND GENERAL INFORMATION
The Scientific Sessions will be held on November 9-10, 2017 at the Regina Elena National Cancer Institute - “Raffaele Bastianelli” Congress Centre (via Fermo Ognibene, 23 - 00144 Rome).
Language
The official language of the Congress is English. Simultaneous translation will not be provided.
Certicate of attendance
Certificates will be issued to all registered participants who will expressly make request at the Secretariat Desk at the end of the Congress.
CME Credits
The Congress will apply for CME Credits.
REGISTRATION INFORMATION
• Registration Fee € 183,00 (VAT 22% included)
• Registration for doctors of Regina Elena
National Cancer Institute FREE
• Post graduate students FREE
The registration fee entitles delegates to the following:
• entry to scientific sessions
• 1 coffee break and 1 buffet lunch on November 9 and 10, 2017
• CME credits
• congress material
• certificate of attendance
For further information or to register please visit the official website:
http://web.aimgroupinternational.com/2017/breastcancer or write to: [email protected]
LOCAL SCIENTIFIC COORDINATORS Alessandra Fabi
LOCAL SCIENTIFIC COMMITTEE Daniele Alesini
Simona Gasparro Paola Malaguti SCIENTIFIC COMMITTEE
P. Conte (Padua, I)
M. De Laurentiis (Naples, I) S. De Placido (Naples, I) L. Del Mastro (Genoa, I) A. Di Leo (Prato, I) S. Gori (Negrar-VR, I) P. Pronzato (Genoa, I)
AIM Education - Provider n. 93
Via G. Ripamonti, 129 - 20141 Milan, Italy Ph. +39 02 56601.1 - Fax +39 02 70048585 [email protected] - www.aimeducation.it
AIM Group International
Rome Office
Via Flaminia, 1068 - 00189 Rome
Ph. +39 06 33053.1 - Fax +39 06 33053249 [email protected]
http://web.aimgroupinternational.com/2017/breastcancer
CME PROVIDER ORGANIZING SECRETARIAT
09.00 Lecture
The tumor microenvironment in breast cancer growth and progression (TBD)
1
STSESSION
HER2 POSITIVE TUMORS Chairmen: F. Puglisi, C. Tondini
09.20 New biology concepts (G. Curigliano)
09.40 Optimizing neoadjuvant and adjuvant treatment (H. Burstein)
10.00 When do you add an endocrine drug to the Her2 dual blockade? (TBD) 10.20 Treatment duration of HER2-directed agents in metastatic disease (E. Perez) 10.40 Drug resistance: mechanism and clinical results (M. Scaltriti)
11.00 The use of biosimilars (R. Danesi) 11.20 Coffee Break
2
NDSESSION
LUMINAL TUMORS
Chairmen: S. Gori, G. Tortora
11.30 The intestinal microbiome (F. Scaldaferri)
11.50 CD4/6 inhibitors: the role in the adjuvant/neoadjuvant setting (M. Cristofanilli) 12.10 New PI3K inhibitors (G. Curigliano)
3
RDSESSION
TRIPLE NEGATIVE Chairman: G. Mustacchi 12.30 Lecture
Insights into the biology: new molecular classification for identifying immuno therapeutics targets (K. Willard - Gallo)
12.50 New Developments in the Treatment of advanced diseases and biomarkers evidence (M.J. Duffy)
13.10 Neo/adjuvant systemic therapy today (M. Cristofanilli) 13.30 Lunch
4
THSESSION
BRCA AND NEW OPINIONS Chairmen: S. Cinieri, L. Del Mastro
14.00 Surgical update in patients with early disease and BRCA mutation (V. Sacchini) 14.20 Novel drugs and new trials in BRCA mutated patients (J. Crown)
14.40 Fertility and BRCA mutation (M. Lambertini)
5
THSESSION
IMMUNOSYSTEM AND IMMUNOTHERAPY Chairman: S. De Placido
15.00 Lecture
Immunotherapy: what we still need to know? (E. Perez) 15.20 New immunotargets in breast cancer (G. Bianchini)
15.40 The combination with nanoparticle molecules (M. De Laurentiis) 16.00 Discussion
6
THSESSION
NEW CONCEPTS Chairman: E. Bria
16.20 From phase I-III to new clinical trials methodologies in breast cancer (P. Bruzzi) 16.40 Trials on druggable mutations, regulatory implications (S. Vella)
Presenting: P. Giacomini 16.50 Lecture
Precision medicine in breast cancer today (David B. Solit)
Presenting: F. Cognetti Lecture
09.00 Breast cancer chemo-prevention (A. De Censi)
7
THSESSION
SUPPORTIVE CARE AND LIFESTYLE Chairmen: V. Adamo, F. Roila
09.20 Toxicity induced by therapy: the new profile of the oncologist (D. Santini)
THURSDAY, NOVEMBER 9
FRIDAY, NOVEMBER 10
09.40 Muscoloskeletal symptoms induced by aromatase inhibitors: new therapeutic approach (C.L. Loprinzi)
10.00 Low-fat diet: is it really a predictor for the best outcome? (R.T. Chlebowsky) 10.20 Physical exercise and breast cancer: risk correlation to subtype and therapeutic effect (D.C. McKenzie)
10.40 Lecture
Adjuvant therapy in HER2 positive early breast cancer: for whom? How long?
With what? (P.F. Conte)
11.00 Coffee Break
8
THSESSION
EVOLVING MOLECULES Chairman: V. Guarneri
11.10 Etirinotecal pegol: in which position in the future clinical choice? (C.J. Twelves) 11.30 Trop-2: potential target for antibody-drug conjugates (A. Bardia)
9
THSESSION
HORMONAL THERAPY AND NOVEL DISCOVERIES IN DRUG RESISTANCES Chairmen: G. Arpino, A. Fabi
11.50 Lecture
Mechanism and clinical results in ER positive patients (A. Di Leo) 12.10 New selective estrogen receptor antagonist (R.S. Finn)
12.30 Lecture
Clinical utility of multigene assays and outcome of disease (TBD)
10
THSESSION
AGE AND BREAST CANCER Chairmen: A. Gennari, U. Tirelli
12.50 Evaluation and treatment of older patients (in early stage) (L.M. Repetto) 13.10 The treatment of Metastatic disease in elderly patients, light and shadow
(C. Fontanella)
13.30 Discussion and Conclusions 14.00 Lunch
